Axillary Lymph Node Status and neoadjuvant Therapy in HER2-positive Breast Cancer

被引：0
|
作者：
Danzinger, Autoren S. [1 ]
Pfeifer, C. [2 ]
Wimmer, S. [1 ]
Tendl-Schulz, K. [3 ]
Singer, C. F. [1 ]
机构：
[1] Med Univ Wien, Inst Univ Klin Frauenheilkunde 1, Vienna, Austria
[2] Univ Innsbruck, Inst Stat, Innsbruck, Austria
[3] Med Univ Wien, Klin Inst Pathol, Vienna, Austria
来源：
GEBURTSHILFE UND FRAUENHEILKUNDE | 2021年 / 81卷 / 04期
关键词：
D O I：
10.1055/s-0041-1726593
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
16
引用
收藏
页码：E6 / E6
页数：1
相关论文
共 50 条
  • [41] Therapy Standards in HER2-Positive Breast Cancer
    Gluz, Oleg
    Liedtke, Cornelia
    Marme, Frederik
    Thill, Marc
    BREAST CARE, 2016, 11 (02) : 148 - 150
  • [42] Axillary lymph node dissection after neoadjuvant chemotherapy for node-positive breast cancer.
    Van Zeeland, M.
    Westhoff, P.
    Wauters, C.
    Bult, P.
    Werner, A.
    Laurens, N.
    Strobbe, L.
    Meijer, H.
    RADIOTHERAPY AND ONCOLOGY, 2020, 152 : S519 - S519
  • [43] Clinical study of stained region lymph node biopsy (SrLNB) in axillary surgery after neoadjuvant systemic therapy in patients with axillary lymph node positive breast cancer
    Wang, Jue
    Chen, Rui
    Li, Cuiying
    Zha, Hailing
    Zhu, Qiannan
    Huang, Lifeng
    Zha, Xiaoming
    CANCER RESEARCH, 2024, 84 (09)
  • [44] Alterations in HER2 status and outcome following neoadjuvant chemotherapy in HER2-positive breast cancer (BC)
    Ng, Dianna
    Krings, Gregor
    Yau, Christina
    White, Kristie
    Hou, Jie
    Chua, Anthony
    Grenert, James P.
    Chen, Yunn-Yi
    CANCER RESEARCH, 2015, 75
  • [45] Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive
    Van Calster, Ben
    Bempt, Isabelle Vanden
    Drijkoningen, Maria
    Pochet, Nathalie
    Cheng, Jiqiu
    Van Huffel, Sabine
    Hendrickx, Wouter
    Decock, Julie
    Huang, Huei-Jean
    Leunen, Karin
    Amant, Frederic
    Berteloot, Patrick
    Paridaens, Robert
    Wildiers, Hans
    Van Limbergen, Erik
    Weltens, Caroline
    Timmerman, Dirk
    Van Gorp, Toon
    Smeets, Ann
    Van den Bogaert, Walter
    Vergote, Ignace
    Christiaens, Marie-Rose
    Neven, Patrick
    BREAST CANCER RESEARCH AND TREATMENT, 2009, 113 (01) : 181 - 187
  • [46] Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive
    Ben Van Calster
    Isabelle Vanden Bempt
    Maria Drijkoningen
    Nathalie Pochet
    Jiqiu Cheng
    Sabine Van Huffel
    Wouter Hendrickx
    Julie Decock
    Huei-Jean Huang
    Karin Leunen
    Frederic Amant
    Patrick Berteloot
    Robert Paridaens
    Hans Wildiers
    Erik Van Limbergen
    Caroline Weltens
    Dirk Timmerman
    Toon Van Gorp
    Ann Smeets
    Walter Van den Bogaert
    Ignace Vergote
    Marie-Rose Christiaens
    Patrick Neven
    Breast Cancer Research and Treatment, 2009, 113 : 181 - 187
  • [47] Pertuzumab in neoadjuvant treatment of HER2-positive early breast cancer
    Abraham, Jame
    JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2014, 12 (03): : 84 - 86
  • [48] Predictors of successful neoadjuvant treatment in HER2-positive breast cancer
    Hannikainen, Elli-Noora
    Mattson, Johanna
    Karihtala, Peeter
    ONCOLOGY LETTERS, 2023, 26 (04)
  • [49] Current neoadjuvant treatment options for HER2-positive breast cancer
    Abdel-Razeq, Hikmat
    Marei, Lina
    BIOLOGICS-TARGETS & THERAPY, 2011, 5 : 87 - 94
  • [50] Predictive factors of resistance to trastuzumab as neoadjuvant therapy in women with HER2-positive breast cancer
    Jinno, Hiromitsu
    Sato, Tomomi
    Takahashi, Maiko
    Hayashida, Tetsu
    Hirose, Shigemichi
    Kitagawa, Yuko
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26)
12345